Industry News
Research, Science & Manufacturer Updates
Several states have introduced legislation that would let patients bypass the U.S. Food and Drug Administration’s (FDA) Expanded Access program in acquiring investigational therapies.
A final rule issued by the Centers for Medicare and Medicaid Services is intended to maintain the rigor of the Medicare Shared Savings program (created by the Affordable Care Act),while ensuring providers continue to participate.
A new simulation study that evaluated the relationship between Guillain-Barré syndrome (GBS) risk and influenza vaccine and illness suggests that the vaccine reduces the risk for GBS.
Researchers investigated the role of one or more pertussis vaccinations in preventing pertussis-related deaths and risk markers for death among infants aged younger than 42 days.
The Alere i influenza A and B test developed and marketed by Alere Inc. has been granted a Clinical Laboratory Improvement Amendments (CLIA) waiver by the U.S. Food and Drug Administration (FDA).
According to the 2013 National HealthInterview Survey, the most recent report used by the Centers for Disease Control and Prevention (CDC), only 29.6 percent of adults ages 18 to 48 receive the flu vaccine, and that number increases to 46.5 percent for adults ages 50 to 64and 67.9 percent for adults over 68.
Nationwide, nearly 11.7 million consumers selected or were automatically re-enrolled in health insurance coverage through the Health Insurance Marketplace as of Feb. 22, according to a report by the U.S. Department of Health and Human Services.
Octapharma USA has launched the Octapharma Co-Pay Assistance Program available to von Willebrand’s disease patients who are currently receiving Wilate or have a prescription to begin therapy.
Baxter International spun off its Baxter BioScience global biopharmaceutical business into Baxalta, which will focus on developing new treatments for people with orphan diseases and underserved conditions.
The Biosimilars Forum was launched by 11 of the leading biosimilar developers in the U.S.
A new study has found that many influenza-positive patients, including those with high-risk conditions, go undiagnosed in favor of a diagnosis of bacterial disease coinfection.
Results from a human trial of GlaxoSmithKline’s Ebola vaccine show it is safe and generates an immune response.